Bile acid resins (cholestyramine, colestipol, Colesevelam) decrease serum cholesterol by inhibiting bile acid recycling through the intestinal Lumen.
The decreased reabsorption of cholesterol results in decreased intrahepatic cholesterol concentrations; this causes the liver to increase the expression of the LDL receptors that bind plasma LDL and ultimately lower serum LDL/cholesterol.
vs. HMG-CoA reductase inhibitors (statins) = inhibiting hepatic cholesterol synthesis. They also ^ hepatic LDL receptors and thus decrease circulating levels of LDL.
submitted by โnamesthegame22(13)
Bile acid resins (cholestyramine, colestipol, Colesevelam) decrease serum cholesterol by inhibiting bile acid recycling through the intestinal Lumen.
The decreased reabsorption of cholesterol results in decreased intrahepatic cholesterol concentrations; this causes the liver to increase the expression of the LDL receptors that bind plasma LDL and ultimately lower serum LDL/cholesterol.
vs. HMG-CoA reductase inhibitors (statins) = inhibiting hepatic cholesterol synthesis. They also ^ hepatic LDL receptors and thus decrease circulating levels of LDL.